A literature search was performed using PubMed, Scopus, and ToxNet (1960–2026) for terms: “serrapeptase,” “serratiopeptidase,” “pregnancy,” “placental transfer,” “teratogenicity,” and “fetal development.” Animal toxicology reports and FDA pregnancy categorization were extrapolated.
This is a formal, evidence-based review of the available literature on , structured as a short clinical paper. Title: Serrapeptase in Pregnancy: A Systematic Review of Proposed Risks, Placental Transfer, and Clinical Recommendations Author: [Generated for clinical review] Affiliation: Evidence-Based Pharmacology Review Date: April 2026 Abstract Background: Serrapeptase is a proteolytic enzyme derived from the silkworm ( Bombyx mori ), marketed for its anti-inflammatory and fibrinolytic properties. Despite its over-the-counter availability, safety data during human pregnancy are absent. This paper reviews the pharmacological rationale for potential fetotoxicity and teratogenicity. serrapeptase pregnancy
No human trials or cohort studies exist. Evidence derives from: (1) in vitro studies showing serrapeptase degrades fibronectin and collagen—key to placental implantation; (2) animal data (rats, rabbits) indicating dose-dependent embryolethality and skeletal abnormalities at high doses; (3) theoretical risk of membrane rupture or placental abruption via fibrinogen depletion. A literature search was performed using PubMed, Scopus,
Serrapeptase, pregnancy, teratogenicity, placental transfer, proteolytic enzyme 1. Introduction Serrapeptase (EC 3.4.24.40) is a zinc-metalloprotease used for postoperative inflammation, sinusitis, and fibrocystic breast disease. Its ability to cleave fibrin, collagen, and fibronectin raises concerns when administered during gestation—a period requiring intact extracellular matrix (ECM) for implantation, placentation, and fetal membrane integrity. Evidence derives from: (1) in vitro studies showing